◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › BMY

Bristol-Myers Squibb Company (BMY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-07-13

Bristol-Myers Squibb Company (BMY) operates in the Pharmaceuticals industry and is headquartered in Princeton, United States with about 32,500 employees. Its market capitalization is roughly $127 billion. In the fiscal year ended 2025-12-31, BMY reported $48.2B in revenue and $7.1B in net income.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Interactive charts & full statements → Open the BMY valuation workbench →

BMY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$48.5B	$48.2B	$48.3B	$45.0B	$46.2B	$46.4B	$42.5B	$26.1B	$22.6B	$20.8B	$19.4B	$16.6B	$15.9B	$16.4B	$17.6B	$21.2B	$19.5B	$18.8B	$20.6B	$19.3B	$17.9B
Gross Profit	$33.3B	$32.6B	$27.4B	$25.4B	$26.5B	$26.8B	$21.7B	$17.2B	$16.1B	$15.0B	$14.5B	$12.8B	$12.0B	$11.8B	$13.2B	$15.7B	$14.3B	$13.8B	$14.4B	$13.2B	$11.7B
Gross Margin %	68.8%	67.7%	56.8%	56.3%	57.4%	57.7%	51.0%	66.0%	71.2%	72.0%	74.6%	77.3%	75.6%	72.0%	74.8%	74.0%	73.6%	73.2%	70.1%	68.3%	65.2%
Operating Income (EBIT)	$12.4B	$12.7B	$9.7B	$8.5B	$9.3B	$9.5B	$4.5B	$6.4B	$6.4B	$5.2B	$5.2B	$3.9B	$3.1B	$3.1B	$4.3B	$6.8B	$6.1B	$5.0B	$4.9B	$3.8B	$2.6B
Operating Margin %	25.7%	26.3%	20.0%	18.8%	20.1%	20.6%	10.6%	24.6%	28.3%	25.2%	26.7%	23.8%	19.7%	19.1%	24.2%	31.8%	31.5%	26.8%	23.7%	19.5%	14.8%
Net Income	$7.3B	$7.1B	($8.9B)	$8.0B	$6.3B	$7.0B	($9.0B)	$3.4B	$4.9B	$1.0B	$4.5B	$1.6B	$2.0B	$2.6B	$2.0B	$3.7B	$3.1B	$10.6B	$5.2B	$2.2B	$1.6B
Net Margin %	15.0%	14.6%	-18.5%	17.8%	13.7%	15.1%	-21.2%	13.2%	21.8%	4.9%	22.9%	9.4%	12.6%	15.6%	11.1%	17.5%	15.9%	56.4%	25.5%	11.2%	8.8%
EBITDA	$13.7B	$14.5B	$3.2B	$19.4B	$19.2B	$20.1B	$4.9B	$7.4B	$6.8B	$6.1B	$6.5B	$2.6B	$3.1B	$3.9B	$3.2B	$7.8B	$6.8B	$6.5B	$5.9B	$4.4B	$3.3B
Earnings Per Share (EPS)	$3.57	$3.46	$-4.41	$3.86	$2.95	$3.12	$-3.98	$2.01	$3.01	$0.61	$2.65	$0.93	$1.20	$1.54	$1.16	$2.16	$1.80	$5.37	$2.62	$1.09	$0.81
Shares Outstanding (M)	2,044M	2,041M	2,027M	2,078M	2,146M	2,245M	2,258M	1,712M	1,637M	1,652M	1,680M	1,679M	1,670M	1,662M	1,688M	1,717M	1,727M	1,978M	2,001M	1,980M	1,963M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$11.5B	$12.5B	$12.2B	$12.3B	$11.2B	$12.3B	$11.9B	$12.2B
Gross Profit	$8.1B	$8.4B	$8.8B	$8.1B	$7.3B	$7.4B	$6.6B	$6.8B
Gross Margin %	70.2%	67.2%	71.9%	65.8%	65.5%	60.2%	55.6%	55.7%
Operating Income (EBIT)	$3.3B	$1.4B	$3.6B	$4.1B	$3.5B	$2.5B	$2.3B	$2.6B
Operating Margin %	28.5%	11.3%	29.8%	33.6%	31.4%	20.5%	19.2%	21.2%
Net Income	$2.7B	$1.1B	$2.2B	$1.3B	$2.5B	$72M	$1.2B	$1.7B
Net Margin %	23.3%	8.7%	18.0%	10.7%	21.9%	0.6%	10.2%	13.8%
EBITDA	$3.7B	$2.2B	$4.6B	$3.3B	$4.5B	$2.6B	$4.8B	$4.4B
Earnings Per Share (EPS)	$1.31	$0.53	$1.08	$0.64	$1.21	$0.04	$0.60	$0.83
Shares Outstanding (M)	2,044M	2,041M	2,038M	2,038M	2,037M	2,037M	2,031M	2,029M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$13.3B	$14.2B	$15.2B	$13.9B	$13.1B	$16.2B	$14.1B	$8.1B	$7.1B	$5.3B	$3.1B	$2.1B	$3.1B	$3.5B	$6.9B	$4.8B	$4.5B	$4.1B	$3.7B	$3.2B	$2.1B
Capital Expenditures (CapEx)	$1.4B	$1.3B	$1.2B	$1.2B	$1.1B	$973M	$753M	$836M	$951M	$1.1B	$1.2B	$820M	$526M	$537M	$548M	$367M	$424M	$730M	$941M	$843M	$793M
Free Cash Flow (FCF)	$11.9B	$12.8B	$13.9B	$12.7B	$11.9B	$15.2B	$13.3B	$7.2B	$6.1B	$4.2B	$1.8B	$1.3B	$2.6B	$3.0B	$6.4B	$4.5B	$4.1B	$3.3B	$2.8B	$2.3B	$1.3B
FCF Margin %	24.6%	26.7%	28.9%	28.1%	25.9%	32.8%	31.3%	27.7%	27.1%	20.3%	9.5%	7.8%	16.5%	18.4%	36.3%	21.1%	20.9%	17.7%	13.4%	11.9%	7.2%
Dividends Paid	$5.1B	$5.0B	$4.9B	$4.7B	$4.6B	$4.4B	$4.1B	$2.7B	$2.6B	$2.6B	$2.5B	$2.5B	$2.4B	$2.3B	$2.3B	$2.3B	$2.2B	$2.5B	$2.5B	$2.2B	$2.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$1.1B	$2.0B	$6.3B	$3.9B	$2.0B	$4.4B	$5.6B	$2.3B
Capital Expenditures (CapEx)	$347M	$370M	$320M	$361M	$260M	$378M	$324M	$262M
Free Cash Flow (FCF)	$757M	$1.6B	$6.0B	$3.6B	$1.7B	$4.1B	$5.3B	$2.1B
FCF Margin %	6.6%	12.8%	49.0%	29.0%	15.1%	32.9%	44.3%	16.9%
Dividends Paid	$1.3B	$1.3B	$1.3B	$1.3B	$1.3B	$1.2B	$1.2B	$1.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMY Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$86.5B	$90.0B	$92.6B	$95.2B	$96.8B	$109.3B	$118.5B	$129.9B	$35.0B	$33.6B	$33.7B	$31.7B	$33.7B	$38.6B	$35.9B	$33.0B	$31.1B	$31.0B	$29.5B	$26.2B	$25.6B
Cash & Cash Equivalents	$9.6B	$10.2B	$10.3B	$11.5B	$9.1B	$14.0B	$14.5B	$12.3B	$6.9B	$5.4B	$4.2B	$2.4B	$5.6B	$3.6B	$1.7B	$5.8B	$5.0B	$7.7B	$8.0B	$1.8B	$2.0B
Total Liabilities	$66.4B	$71.5B	$76.2B	$65.7B	$65.7B	$73.3B	$80.6B	$78.2B	$20.9B	$21.7B	$17.4B	$17.3B	$18.8B	$23.4B	$22.3B	$17.1B	$15.4B	$16.2B	$17.3B	$15.6B	$15.6B
Total Debt (Short + Long-Term)	$44.5B	$45.3B	$49.8B	$39.9B	$39.5B	$44.7B	$50.8B	$46.9B	$7.3B	$8.0B	$6.7B	$6.7B	$7.8B	$8.3B	$7.4B	$5.5B	$5.4B	$6.4B	$6.7B	$6.3B	$7.4B
Total Shareholders' Equity	$20.1B	$18.5B	$16.3B	$29.4B	$31.1B	$35.9B	$37.8B	$51.6B	$14.0B	$11.7B	$16.2B	$14.3B	$14.9B	$15.2B	$13.6B	$16.0B	$15.7B	$14.8B	$12.2B	$10.6B	$10.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BMY viewer.

Other Companies in Pharmaceuticals

LLY · Lilly (Eli) — $1.07 trillion
JNJ · Johnson & Johnson — $635 billion
MRK · Merck & Co. — $324 billion
PFE · Pfizer — $140 billion
ZTS · Zoetis — $32 billion
VTRS · Viatris — $20 billion

← BMRN All stocks BN →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.